KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.

MLA

Graham, Lara V., et al. “KIR2DS2+ NK Cells in Cancer Patients Demonstrate High Activation in Response to Tumour-Targeting Antibodies.” Frontiers in Oncology, Sept. 2024, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fonc.2024.1404051.

APA

Graham, L. V., Fisher, J. G., Doyle, A. D. P., Sale, B., Del Rio, L., French, A. J. E., Mayor, N. P., Turner, T. R., Marsh, S. G. E., Cragg, M. S., Forconi, F., Khakoo, S. I., & Blunt, M. D. (2024). KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies. Frontiers in Oncology, 1–11. https://doi.org/10.3389/fonc.2024.1404051

Chicago

Graham, Lara V., Jack G. Fisher, Amber D. P. Doyle, Ben Sale, Luis Del Rio, Albert J. E. French, Neema P. Mayor, et al. 2024. “KIR2DS2+ NK Cells in Cancer Patients Demonstrate High Activation in Response to Tumour-Targeting Antibodies.” Frontiers in Oncology, September, 1–11. doi:10.3389/fonc.2024.1404051.